DYN — Dyne Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1818794 ·
Last close
$23.42
Market Cap
$3.87B
52W High
$24.60
52W Low
$15.87
ADV30
2,140,398
Next earnings
2026-07-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -125,276,000 | -120,854,000 | 1,079,950,000 | 753,102,000 | 214,895,000 |
| Dec 2025 | 0 | — | -116,129,000 | -111,955,000 | 1,186,958,000 | 893,369,000 | 214,829,000 |
| Sep 2025 | 0 | — | -113,892,000 | -108,041,000 | 867,059,000 | 573,610,000 | 175,276,000 |
| Jun 2025 | 0 | — | -115,791,000 | -110,857,000 | 728,992,000 | 485,040,000 | 157,547,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-442,236,000
Investing CF
$-32,601,000
Financing CF
$756,130,000
CapEx
$-19,950,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.22
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,516,996,000
Inventory
—
Receivables
—
ST Investments
$219,054,000
EBIT TTM
$-441,313,000
Pretax Income TTM
$-451,707,000
Interest Exp TTM
$10,394,000
Analysts
16
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -468,184,000 | -446,214,000 | 1,186,958,000 | 214,829,000 | — | -403,207,000 |
| Dec 2024 | 0 | -343,886,000 | -317,418,000 | 691,234,000 | 61,396,000 | — | -292,369,000 |
| Dec 2023 | 0 | -242,162,000 | -235,937,000 | 165,082,000 | 73,790,000 | — | -188,158,000 |
| Dec 2022 | 0 | -170,962,000 | -168,099,000 | 306,325,000 | 53,961,000 | — | -153,645,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.00
Max Pain — expiry 2026-12-18
max pain strike: $22.50 · spot: $23.42 · call oi: 497 · put oi: 2,599
Expected Move to 2026-12-18:
±$7.50
(32.02%) —
implied range
$15.92 –
$30.92
· ATM straddle on $22.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CPRX | CATALYST PHARMACEUTICALS, INC. | $3.85B | $31.47 | — |
| GPCR | Structure Therapeutics Inc. | $3.79B | $53.36 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.77B | $11.14 | — |
| ELVN | Enliven Therapeutics, Inc. | $3.65B | $51.09 | — |
| RCUS | Arcus Biosciences, Inc. | $3.64B | $28.92 | — |
News headlines (Yahoo Finance, 1h cache)
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
2026-07-04 13:41 · Yahoo
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
2026-07-01 15:58 · Yahoo
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-26 15:25 · Yahoo
Dyne Therapeutics Appoints Barry Greene to Board of Directors
2026-06-22 20:10 · Yahoo
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-18 20:05 · Yahoo
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
2026-06-17 11:30 · Yahoo
Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment
2026-06-11 10:20 · Yahoo
Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone
2026-06-05 15:55 · Yahoo
A Look At Dyne Therapeutics (DYN) Valuation After Key ACHIEVE Trial Enrollment Milestone
2026-06-05 03:15 · Yahoo
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
2026-06-03 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.